Eptifibatide: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Intravenous
Unstable angina

Adult: Initially, 180 mcg/kg via IV inj, followed by 2 mcg/kg per minute via IV infusion for up to 72 hr. Continue infusion for 18-24 hr after percutaneous coronary intervention (PCI) procedure, up to total max duration of 96 hours of therapy.

Intravenous
Angioplasty

Adult: Initially, 180 mcg/kg via IV inj, to be given immediately before procedure, followed by 2 mcg/kg/minute via IV infusion. A second dose of 180 mcg/kg via IV inj should be given 10 minutes after the 1st dose. Continue infusion until hospital discharge or for up to 18-24 hr (minimum treatment duration: 12 hr).

Renal Impairment

Intravenous:
Angioplasty: Dose reduction may be needed. See Lit.

CrCl (mL/min)	Dosage
<30	Contraindicated.

Unstable angina: Dose reduction may be needed. See Lit.

CrCl (mL/min)	Dosage
<30	Contraindicated.

Contraindications

Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.

Special Precautions

Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm³; hemorrhagic retinopathy, drugs affecting haemostasis. Check aPTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy.

Adverse Reactions

Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.

Pregnancy Category (US FDA)

IV/Parenteral: B

Drug Interactions

Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.

Action

Description:
Mechanism of Action: Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis. [PubMedID: 21211597]
Onset: Within 1 hr.

MIMS Class

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

Disclaimer: This information is independently developed by MIMS based on Eptifibatide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com